EBITDA: Income before interest, taxes, depreciation and amortization.
Eupraxia Pharmaceuticals Inc. (T.EPR) had EBITDA of -53.39M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
-57.46M |
|
-- |
|
-- |
|
-- |
|
-53.72M |
|
-- |
|
-53.93M |
|
-53.93M |
|
-53.96M |
|
-53.96M |
|
-53.96M |
|
-53.96M |
|
-53.72M |
|
|
EBITDA |
-53.39M |
39.96M |
|
39.96M |
|
-1.44 |
|
-1.44 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
120.41M |
|
-- |
|
-- |
|
-- |
|
7.97M |
|
70.87M |
|
112.44M |
|
112.44M |
|
51.94M |
|
| Cash Flow Statement Financials | |
-39.91M |
|
-0.82M |
|
106.31M |
|
46.27M |
|
112.60M |
|
66.34M |
|
12.24M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
15.12 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-40.73M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-76.13% |
|
-47.99% |
|
-44.81% |
|
-47.94% |
|
2.16 |
|
-1.02 |
|
-1.00 |
|